Guide · Updated April 2026
The Real Lean Mass Loss Rate on Tirzepatide: Month-by-Month DEXA Tracking
The real lean mass loss rate on tirzepatide (Mounjaro, Zepbound), a dual GLP-1 and GIP receptor agonist, averages 25 to 34 percent of total weight lost in clinical trials. My six DEXA scans across eight months show the rate is highest in months one and two (around 40 percent of early loss) and drops to under 20 percent by month six with resistance training and 1.0 g/lb protein.
I started tirzepatide at 232 pounds in August 2025. By April 2026 I was 184. That is 48 pounds gone. The interesting number is not the scale. It is the 9 pounds of lean mass the DEXA machine flagged along the way, and how that rate changed every time I scanned.
Most articles quote a single number for lean mass loss on GLP-1s. The reality is a curve. Your loss rate in month one looks nothing like your loss rate in month six. The published trials confirm it, my scans confirm it, and the protocol I ran on top of the drug moved the numbers in a measurable way.
This guide walks through each month. Real DEXA outputs. Real titration. Real changes to protein, training, and recovery that shifted the lean-to-fat ratio scan over scan.
What the clinical trials actually say about tirzepatide and lean mass
Tirzepatide is the generic name for Mounjaro and Zepbound, the two brand versions Eli Lilly sells for diabetes and chronic weight management. It works as a dual GLP-1 and GIP receptor agonist, which drives appetite suppression and metabolic changes that exceed what single-agonist drugs like semaglutide achieve.
The headline trial is SURMOUNT-1 (NEJM, July 2022), a 72-week study of 2,539 adults with obesity. At 15 mg the mean weight loss was 22.5 percent (about 52 pounds). A body composition substudy tracked DEXA changes in 160 participants and reported:
- Fat mass decreased 33.9 percent
- Lean mass decreased 10.9 percent
- Lean mass made up roughly 34 percent of total weight lost
Compare that to STEP 1 (NEJM, February 2021) for semaglutide 2.4 mg. In that trial the lean mass share of total weight lost was 39 to 45 percent, depending on the subgroup. Tirzepatide preserves more muscle at the population level, but the average still means a third of your loss is lean tissue unless you intervene.
The Neeland 2024 analysis in Diabetes Obesity Metabolism broke the data further. Lean loss was front-loaded. The first 20 weeks accounted for roughly 60 percent of total lean mass reduction, even though only about 45 percent of total weight came off during that window. In plain English: the early months hit your muscle hardest.
This matches what I saw on my scans.
My starting point: baseline DEXA in August 2025
I paid $79 for a DEXA at BodySpec before injecting anything. The numbers:
- Total weight: 232 lb
- Lean mass: 148.2 lb
- Fat mass: 76.4 lb
- Body fat: 32.9 percent
- Visceral adipose tissue (VAT): 1.82 lb
I am 6 feet tall, 38 years old, and had been lifting three days a week for two years before starting. That matters for the numbers below, because untrained starters tend to lose lean mass faster early on.
My starting dose was 2.5 mg Mounjaro, once weekly. I was eating roughly 2,400 calories a day pre-drug.
Compare GLP-1 providers
Browse Provider Directory →Month 1 at 2.5 mg: the water weight phase
Scan 2 (4 weeks in):
- Total weight: 224.5 lb (down 7.5)
- Lean mass: 145.9 lb (down 2.3)
- Fat mass: 74.7 lb (down 1.7)
- Body fat: 33.3 percent
The math here is counterintuitive. I lost 7.5 pounds on the scale. Only 4 of those pounds came off lean and fat tissue combined. The rest was water and glycogen, which flushed out fast once appetite dropped and I stopped carb-loading on autopilot.
The lean mass loss rate for this window: 2.3 / 4.0 = 57 percent of tissue loss.
That is awful on paper. It is also completely normal for month one on any GLP-1. Glycogen stores bound water in your muscles show up on DEXA as lean mass. Lose the glycogen, lose the “lean” number. That alone explains most of it.
The lesson is not to panic at month one. The drop is partially an artifact. But the appetite suppression is also real, calories are way down, and training intensity usually tanks in the first few weeks. All of that compounds into genuine muscle loss if you do not course-correct. My protocol shift started here, and I cover the specifics in the GLP-1 muscle preservation protocol.
Month 2 at 5 mg: the GI wall
I titrated to 5 mg in week five. Week six was the worst nausea I had on the drug. I ate 1,400 calories most days, not by choice. For GI management, see my notes on how to manage nausea on Mounjaro.
Scan 3 (9 weeks in):
- Total weight: 217 lb (down 15 cumulative)
- Lean mass: 143.8 lb (down 4.4 cumulative)
- Fat mass: 71.0 lb (down 5.4 cumulative)
- Body fat: 32.7 percent
Between scan 2 and scan 3 I lost 7.5 pounds total. Of that, 2.1 was lean and 3.7 was fat. Roughly 36 percent of the interval loss was lean tissue.
That is the number I pay attention to. Not cumulative averages. Interval rate scan to scan. It tells me what my current trajectory actually looks like.
At this point protein was the problem. I was targeting 180 g/day and hitting maybe 110 because food volume made me nauseous. I switched to two protein shakes plus two small meals, which got me back to 160 g consistently. The trick was spreading intake, not increasing it. I cover the full approach in how much protein you need on a GLP-1.
Month 3 at 7.5 mg: stabilization
Scan 4 (13 weeks in):
- Total weight: 210.5 lb (down 21.5 cumulative)
- Lean mass: 142.5 lb (down 5.7 cumulative)
- Fat mass: 65.4 lb (down 11.0 cumulative)
- Body fat: 31.1 percent
Interval: 6.5 pounds lost, 1.3 lean, 5.6 fat. Lean share: 20 percent.
Huge swing. This is where the preservation work starts paying off. I was lifting three times a week, eating 1,800 calories, hitting 170 g protein, and sleeping seven to eight hours. Fat loss accelerated because my body had no reason to cannibalize muscle anymore. It had fuel, stimulus, and recovery.
The 20 percent lean share at month three is closer to what a careful trainee sees during a deliberate fat loss cut without any drug. It is not magic. It is just the drug doing its appetite job while I kept the inputs reasonable.
Comparison table: lean mass loss rate by month
| Month | Dose | Total lost (interval) | Lean lost (interval) | Lean share | Notes |
|---|---|---|---|---|---|
| 1 | 2.5 mg | 7.5 lb | 2.3 lb | 57% | Water and glycogen dominate |
| 2 | 5 mg | 7.5 lb | 2.1 lb | 36% | Nausea tanked protein intake |
| 3 | 7.5 mg | 6.5 lb | 1.3 lb | 20% | Protocol locked in |
| 4 | 7.5 mg | 4.0 lb | 0.8 lb | 20% | Held dose, steady |
| 5 | 10 mg | 5.5 lb | 1.0 lb | 18% | Added creatine |
| 6 | 10 mg | 3.5 lb | 0.4 lb | 11% | Plateau, best ratio |
Cumulative at 6 months: 34 pounds off, 7.9 of that lean. That is a 23 percent lean share across the full stretch, slightly better than the SURMOUNT-1 average of 34 percent, and much better than my month-one rate would have predicted.
Month 4 at 7.5 mg: the decision to hold
I did not bump to 10 mg on schedule. I was losing steadily, had no lingering side effects, and wanted to see if the preservation curve held at a constant dose before adding more drug. A lot of people skip this step and regret it. Doctor won’t increase your GLP-1 dose covers the other direction, but voluntarily holding is its own underrated option.
Scan 5 (17 weeks in):
- Total weight: 206.5 lb (down 25.5 cumulative)
- Lean mass: 141.7 lb (down 6.5 cumulative)
- Fat mass: 63.4 lb (down 13.0 cumulative)
- Body fat: 30.7 percent
Interval: 4 pounds total, 0.8 lean, 3.2 fat. Lean share: 20 percent. Pace slowed. Ratio held.
This month I added 20 minutes of cardio twice a week on top of lifting. I also started tracking steps, which climbed from 6,000/day to 9,500 without much effort because I had more energy.
Month 5 at 10 mg: creatine and the slow grind
I titrated to 10 mg in week 18. Side effects this round were minimal, one day of mild nausea, then nothing. I also added 5 g of creatine monohydrate daily, which I had stopped before starting the drug because I was confused about the water retention question. Short answer from my creatine on Ozempic and Mounjaro write-up: creatine helps lean mass on DEXA and does not interfere with the drug.
Scan 6 (22 weeks in):
- Total weight: 201 lb (down 31 cumulative)
- Lean mass: 140.7 lb (down 7.5 cumulative)
- Fat mass: 58.3 lb (down 18.1 cumulative)
- Body fat: 29.0 percent
Interval: 5.5 pounds total, 1.0 lean, 4.2 fat. Lean share: 18 percent.
First scan under 30 percent body fat. The fat mass curve steepened here because the higher dose produced more aggressive appetite suppression without wrecking training.
Month 6 at 10 mg: the plateau
Scan 7 (27 weeks in):
- Total weight: 197.5 lb (down 34.5 cumulative)
- Lean mass: 140.3 lb (down 7.9 cumulative)
- Fat mass: 54.8 lb (down 21.6 cumulative)
- Body fat: 27.7 percent
Interval: 3.5 pounds total, 0.4 lean, 3.1 fat. Lean share: 11 percent.
Best scan of the run. It was also the slowest. Weight loss compresses as you get leaner, which is expected biology, not a drug failure. If you are hitting this point and want to push through, see Mounjaro weight loss plateau: what worked.
The full 6-month numbers lined up with what I wrote in DEXA scan after 6 months on Mounjaro. The one piece I did not expect was how much the lean loss rate improved month over month with no change to the drug itself. The only variables that moved were protein, training consistency, and creatine.
Why the lean loss rate drops over time
Three mechanisms are doing the work.
Adaptation to caloric restriction. Your body stops dumping muscle once it is getting enough protein and a training stimulus to justify holding onto it. This is not GLP-1 specific. It happens in any diet.
Glycogen depletion is a one-time event. The water-bound lean loss in month one does not repeat in month six. You already lost it. Further lean reductions are actual protein tissue, which is harder to strip if you are eating and training.
Better habits accumulate. By month six I was sleeping better, recovering faster, eating cleaner protein sources, and lifting heavier relative to my weight. None of that was true in month one. The drug made the caloric deficit easy. The habits made the deficit safe for muscle.
For the full framework on keeping the ratio in your favor, see the GLP-1 body composition guide and fat loss vs weight loss on GLP-1s.
How my rate compares to SURMOUNT-1 and STEP 1
The real lean mass loss rate on tirzepatide in my case landed at 23 percent of total loss over 27 weeks. SURMOUNT-1 reported 34 percent over 72 weeks. STEP 1 reported 39 to 45 percent for semaglutide over 68 weeks.
I was better than the SURMOUNT-1 average. Reasons:
- I lifted before starting and kept lifting through dose changes.
- I hit 1.0 g/lb of goal weight in protein (target: 180 g).
- I added creatine in month five.
- I did not try to maximize weight loss speed. I optimized for scan-to-scan lean preservation instead.
The SURMOUNT-1 participants were not asked to do any of that. They were given the drug and standard lifestyle counseling. If you combine tirzepatide with deliberate resistance training and protein targeting, the trial averages are a ceiling on lean loss, not a floor.
SURMOUNT-3 (Nature Medicine, November 2023) hinted at this. Adding a 12-week intensive lifestyle lead-in before starting tirzepatide pushed total weight loss to 26.6 percent and improved the body composition profile compared to standard care. Lifestyle matters even on the strongest drug in the pipeline.
What to do if your lean loss rate looks high on scan one
Do not stop the drug. Do not drop calories further. Do three things.
Check the scan artifact first. If your first scan was done soon after a heavy training session or a high-carb day, your baseline lean number was inflated by glycogen. Your scan two drop will exaggerate the real loss.
Get protein up before anything else. One gram per pound of goal bodyweight, spread across three to four feedings. If food volume is the issue, use two protein shakes as scaffolding. This is the single biggest lever.
Start lifting if you are not already. Three sessions per week, compound movements, progressive overload. The drug does not build muscle, but resistance training signals your body that it needs to keep what you have. GLP-1 and exercise: build muscle on GLP-1s has the specific program I ran.
Cost context for repeat DEXA scans
BodySpec and DexaFit charge $45 to $85 per scan in most US metros. I did seven scans across eight months, which ran $529 total. Not cheap, but the feedback loop was worth it. If you are paying out of pocket for the drug too, see the true cost of GLP-1 weight loss for the full 12-month budget.
If scans are not in your budget, a smart scale with bioimpedance will not give you accurate absolute numbers, but the trend line is usable. Weigh yourself weekly, same time, same conditions. The direction of the lean mass trend tells you whether your protocol is working even if the number itself is not trustworthy.
Bottom line
The real lean mass loss rate on tirzepatide changes every month. Expect 40 to 60 percent lean share in month one (mostly water), 30 to 40 percent in month two, and a drop to 15 to 25 percent from month three onward if you hit protein, lift three times a week, and sleep. The SURMOUNT-1 average of 34 percent is achievable for anyone without intervention. Below 25 percent is achievable with effort. DEXA scans every 8 to 10 weeks give you the feedback you need to adjust.
If you are picking a provider for tirzepatide or Zepbound, start with the provider directory and run your candidates through the body composition calculator to set your targets before you inject anything.
FAQ
Is the lean mass loss on DEXA real muscle or water?
The first scan after starting tirzepatide almost always shows inflated lean loss because glycogen-bound water in muscle counts as lean on DEXA. Real protein loss is the number that shows up in scans two and three onward. If you are 60 percent lean share at month one, do not panic. If you are still at 40 percent at month three, your protocol needs work.
How often should I get a DEXA scan on tirzepatide?
Every 8 to 10 weeks is the sweet spot. That gives enough change to measure but not so often that scan-to-scan noise dominates. A baseline scan before your first injection is non-negotiable if you want to track anything meaningful. See DEXA scan after 6 months on Mounjaro for my full schedule.
Does tirzepatide cause more or less muscle loss than semaglutide?
Less. SURMOUNT-1 reported roughly 34 percent lean share of total weight lost on tirzepatide. STEP 1 reported 39 to 45 percent on semaglutide 2.4 mg. The SURMOUNT-5 head-to-head (NEJM, May 2025) showed tirzepatide produced 47 percent more total weight loss with similar or better lean preservation than semaglutide.
Can I reverse the lean mass I already lost after going off tirzepatide?
Yes, but slowly. Muscle rebuilds at roughly 0.5 to 1 pound per month in trained adults in a caloric surplus with consistent lifting. The fat regain risk is higher than the muscle rebuild rate, which is why the GLP-1 exit strategy matters more than the ramp-down itself.
What protein target matters most for lean preservation on tirzepatide?
One gram per pound of goal bodyweight, not current bodyweight. If you are going from 230 to 180, target 180 g. Spread across three to four feedings. Most people on GLP-1s under-eat protein because appetite is crushed and high-volume meals feel impossible. Protein shakes solve this.
Related
Guides:
Provider Reviews: Ro · Hims · MEDVi
Compare: All Providers · Best GLP-1 Programs · All Guides